Replimune Group, Inc. (REPL)
9.72
-0.10
(-1.02%)
USD |
NASDAQ |
Dec 31, 16:00
9.725
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Research and Development Expense (TTM): 218.21M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Rapt Therapeutics, Inc. | 82.87M |
| Olema Pharmaceuticals, Inc. | 146.78M |
| CorMedix, Inc. | 12.46M |
| Verastem, Inc. | 103.74M |
| Anavex Life Sciences Corp. | 37.59M |